$500m of senior unsecured notes filed recently by $IBP, due 2034. $300m goes to refinancing existing debt. the other $200m is "general corporate purposes." the may 7 10-Q showed a q1 miss and cautious residential guidance. twelve days later they closed diamond energy systems and bought back $51.2m in stock. now they're extending maturities and stacking additional capacity on top. a company flagging soft housing demand doesn't usually layer on incremental debt without a target in mind. watch the next few months for another acquisition or a bigger buyback announcement. wiseek.ai/ticker/ibp/0001628…

$ATOS got the fda "study may proceed" for (z)-endoxifen in metastatic breast cancer, filed recently. real gate cleared. the mbc ind can now move into clinical investigation without a hold. the june 12 424b5 closed a $4.1m registered direct above market. the may 8 10-q carried a going concern warning. same day, stockholders authorized a 2:1 to 20:1 reverse split. ind clearance is meaningful. so is raising $4.1m on a going-concern balance sheet with a split window open. they're in the same filing stack. wiseek.ai/ticker/atos/000119…

$SLXN's RNAi therapy SIL204 is headed into phase 2/3 for locally advanced pancreatic cancer, filed recently with H1 2026 as the trial start window. preclinical data passed, tox studies cleared, regulatory feedback incorporated. the other filings are harder to ignore. 1-for-10 reverse split completed may 29. june 12 S-3 registers 859k shares for selling shareholders. june 3 pre-14a seeks approval for warrant exercisability and another round of share issuances. and a may 29 13D/A has a major shareholder disputing the validity of recent issuances, claiming a 33% stake. q1 net loss of $2.7m on a market cap smaller than that loss. the science may be legitimate. the capital structure is not. wiseek.ai/ticker/slxn/000117…

$12.6b in assumed debt and a $5b-$6b impairment charge. that's what $CHTR disclosed in pro forma financials filed recently for the cox acquisition. the impairment is day-one. before they've operated a single cox line, they're already marking down $5b-$6b of what they paid for it. zoom out: the former ceo filed a form 4 may 28 showing $12.7m in stock sales. two 144s on may 27 showed director and officer intent to sell another $24m . q1 broadband subs missed badly and the stock dropped 20% in april. this deal closes into a bleeding broadband environment. $12.6b more debt, a guaranteed write-down, and the people who know the business best were quietly walking out the door. wiseek.ai/ticker/chtr/000110…

79% of patients hit the nasal polyp score response threshold on verekitug. 72% on nasal congestion. 83% on total symptom score. $UPB reported in the last hour. these aren't the topline numbers from may 18. this is the responder analysis, which is the harder cut. how many individual patients cleared the bar, not just what the mean looked like. the quarterly dosing angle keeps coming up for a reason. CRSwNP is a chronic condition. patients don't want monthly injections indefinitely. if verekitug holds these numbers into phase 3 with that dosing schedule, the differentiation case writes itself. phase 3 in both CRSwNP and severe asthma still penciled in for Q1 2027. cash runway question was flagged in the may 13 10-Q alongside the $40.6m Q1 loss, and the $150m ATM from march is how they're bridging it. wiseek.ai/ticker/upb/news/b8…

$1.16. that's the new conversion price on $WHLR's 7% subordinated convertible notes due 2031, filed recently. it's a 45% discount to wherever the stock was benchmarked when the notes were structured. the notes aren't the only dilution mechanism running. preferred stock redemptions are going simultaneously, so the share count is getting squeezed from two directions at once. they also filed a 1-for-4 reverse split effective june 17. that buys some optical price recovery, but doesn't touch the underlying math. the conversion cliff is still there, just repriced deeper into discount territory. wiseek.ai/ticker/whlr/000152…

$GLTO filed recently disclosing another layer of dilution, this time wrapped around a COO hire. sherwin sattarzadeh joins as chief operating officer, but the same 8-K reveals warrant issuance plus substantial equity compensation for the new exec. this comes three months after the february 11 $295.9M public offering priced at a discount. that deal was already flagged as highly dilutive. now shareholders absorb another round stacked on top of it. the march rebranding to damora therapeutics pointed to $535M cash and an accelerated pipeline. the cost of building that runway keeps showing up in the cap table. wiseek.ai/ticker/glto/000119…

three 6-Ks in the last two weeks from $AEC, each marking a real operational step: phase one at velvet-wood done, mill refurbishment started, now a 2025 recap filed recently with the 2026 production restart thesis spelled out. nasdaq listing done, strategic acquisition closed, and a may PEA showing 97% IRR and $533M NPV on the uranium-vanadium project. the u.s. uranium producer story is there on paper. the one flag: june 10 6-k had shareholders voting on exec comp with high payouts against a low stock price. production hasn't started yet and management is already expensive. wiseek.ai/ticker/aec/0001171…

$BSAC filed recently: 37.3% net income growth through nine months of 2025. three quarters of sustained improvement, not a one-quarter spike. efficiency ratio is moving the right direction. income growing faster than costs is the combination that compounds in a rate-sensitive market. the less-discussed piece: management is planning a partial sale of the Getnet subsidiary. monetizing the payments arm now is a deliberate choice about where valuations are. executive appointments in the same report. they're positioning, not coasting.

$6.0m raise when you're already on delisting watch is not a growth move. $MOBX filed recently pricing a public offering at terms the company itself flagged as "highly dilutive" in the 424b5. layer on top: the june 11 144 shows officer keyvan samini filing intent to sell 118,146 shares. the june 9 defa14a has the company seeking shareholder approval to issue even more shares and register 4.54m for resale. they also signed a drone acquisition loi (vision aerial). buying companies while burning through equity raises and carrying a going concern opinion is a bold sequencing choice. the atm program got cut by $14.5m in the prior 424b5. now they're back with a $6m deal instead. smaller chunks, more frequent dilution. wiseek.ai/ticker/mobx/000149…

$200m to buy out the royalty. $150m equity raise that sent shares down 12%. and now the NDA is in. $MLYS filed recently for FDA approval of lorundrostat, their aldosterone synthase inhibitor targeting resistant hypertension. the june 3 8-k priced that offering at a premium specifically to clean up the IP. so heading into FDA review, they own the drug outright, no royalty overhang. explore-OSA phase 2 data was flagged for Q1 in the filing. a second indication stacked behind the NDA if that readout held up. a lot staked on one compound. FDA clock is running. wiseek.ai/ticker/mlys/000193…

$MIST's EMA accepted the MAA for etripamil nasal spray, filed recently. Q1 2027 is the expected decision window, so european clearance is real but 9 months out. on may 13, same day as the 10-Q showing first product revenue and $75M in royalty financing closed, they filed a $300M universal shelf and $100M at-the-market offering. capital markets wide open right as the commercial phase started. EMA adds a real second geography if it clears. the timeline is long. wiseek.ai/ticker/mist/000110…

four mipi a-phy design wins now for $VLN. the latest, filed recently, is with a premium global auto OEM adding VA7000 chipsets to ADAS systems for the chinese market. production in 2027. each win is a multi-year supply relationship, not a one-time order. the connectivity layer for cameras and sensors in next-gen vehicles is a sticky position once you're designed in. china ADAS is also one of the fastest-moving segments in auto right now. a separate 6-K this month showed a tier 1 e-mirror production win on the same stack. two design wins in short succession, both ADAS. the pipeline is building quietly. wiseek.ai/ticker/vln/0001213…

second delisting notice from $SELX in under a month. the may 22 6-k was for multiple listing rule violations. the 6-k filed recently adds a separate breach: market value of listed securities has fallen below nasdaq's $35m floor. a subsidiary landed a $7m taiwan coast guard UAV pilot contract in the same stretch. real contract, real government customer. but two open compliance deficiencies running simultaneously is a hard position to trade out of. shareholders approved up to a 20:1 reverse split back in april. the clock is now running on both fronts.

$RNAZ filed recently: preclinical data confirms TTX-MC138 suppresses glioblastoma tumors and extends survival in murine models. that stacks on the june 3 phase 1a showing 64% stable disease. two 8-Ks in ten days, both with real positive readouts. glioblastoma is brutal. median survival under 15 months on standard of care. tumor suppression in mice with extended survival isn't nothing. the problem is the company structure. $19.51m q1 net loss against a $6m market cap, a june 2 def 14a putting dilution to a shareholder vote, preferred stock conversion already in motion to hold the nasdaq listing. the science is advancing. the equity isn't. wiseek.ai/ticker/rnaz/000110…

$PRE has been rebuilding itself around IM8 for six months. the europa sale filed recently is the last piece. jay shetty as ambassador and shareholder in may. dedicated IM8 CFO hired may 14. DTC brand CEO added to the board june 4. raised guidance on q1 results june 10. now they've sold the legacy europa 3pl distribution arm for up to $13m and closed the loop. the transformation was already done. europa was just the cleanup. wiseek.ai/ticker/pre/0001628…

$DNLI has a PDUFA coming for tividenofusp alfa in Hunter syndrome, and filed recently with a full 2026 milestone map. pompe disease clinical hold lifted. two alzheimer's programs moving into clinical studies. capital raised to extend runway. the may 21 8-K was a reset moment. biogen and denali walked away from BIIB122 after the phase 2b failure in parkinson's. that program is gone. the question since then was what's actually left standing. this filing lays it out: hunter syndrome binary event ahead, two more alzheimer's bets entering the clinic, and pompe cleared to move. AVLAYAH already approved and launched. they have more live shots than the parkinson's news made it feel like.

$DARE filed recently: commercial launch of sildenafil cream, positive phase 3 interim data for ovaprene, non-dilutive nih funding for dare-hpv. three real pipeline moves in one 8-k. the backdrop is harder. the may 14 10-q puts cash runway at q4 2026. nasdaq delisting risk is live. and the june 12 8-k had shareholders approve 1.5m new shares for the incentive plan. so the science is actually moving. ovaprene's phase 3 is the one that matters most. if that data holds through final readout, they have something. but six months of cash doesn't leave much margin for a slow commercial ramp on the sildenafil cream either.

$CMPX lost 61% in april when the tovecimig trial design flaw hit. the 8-K filed recently doesn't linger there. it pivots hard to CTX-8371, their PD-1/VEGF bispecific, where may phase 1 data showed durable responses in advanced cancer patients. the pitch they're making: accelerated approval pathway for CTX-8371. cash sits around $195m with runway into 2028, which gives them time to build that case without diluting to survive. the question the market is still chewing on: is this a clean asset pivot or is the company leaning on CTX-8371 because tovecimig is radioactive right now. the cash position buys them the luxury of finding out. wiseek.ai/ticker/cmpx/000117…

$101m in debt retired and $76m in buybacks. $PDS filed recently confirming it hit both 2025 capital allocation targets. most drillers treat balance sheet repair and shareholder return as a trade-off. precision ran them in parallel and cleared both marks. that's the part worth noting. the 6-K also includes operational updates, so this wasn't a pure finance announcement. execution held up while they were deleveraging. wiseek.ai/ticker/pds/0001171…